CI vs MET
Cigna Group and Metlife Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CI | MET |
|---|---|---|
| Revenue | $274.9B | $77.1B |
| Net income | $6.0B | $3.4B |
| Gross margin | 21.8% | — |
| Net margin | 2.3% | 4.4% |
| Return on equity | 14.4% | 12.1% |
| Diluted EPS | $22.18 | $4.71 |
| Dividend / share | $6.04 | $2.25 |
| Payout ratio | 27.0% | 44.7% |
| Free cash flow | — | — |
| Equity | $41.7B | $28.4B |
| Net debt / equity | 0.57× | −0.25× |
| Current ratio | 0.85× | — |
| Revenue CAGR 5y | 11.4% | 2.6% |
| Profit CAGR 5y | — | −9.0% |
CI bills 3.6× the revenue of MET, and MET keeps more of each dollar of revenue as profit (4.4% against 2.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | CI | MET |
|---|---|---|
| FY2025 | $274.9B | $77.1B |
| FY2024 | $247.1B | $71.0B |
| FY2023 | $195.3B | $66.9B |
| FY2022 | $180.5B | $68.8B |
| FY2021 | $174.1B | $68.7B |
| FY2020 | $160.4B | $67.8B |
| FY2019 | $153.6B | $69.6B |
| FY2018 | $48.6B | $67.9B |
| FY2017 | $41.8B | $62.3B |
| FY2016 | $39.8B | $60.8B |
Net income by year
Bottom line
| Fiscal year | CI | MET |
|---|---|---|
| FY2025 | $6.0B | $3.4B |
| FY2024 | $3.4B | $4.4B |
| FY2023 | $5.2B | $1.6B |
| FY2022 | $6.8B | $5.3B |
| FY2021 | $5.4B | $6.9B |
| FY2020 | $8.5B | $5.4B |
| FY2019 | $5.1B | $5.9B |
| FY2018 | $2.6B | $5.1B |
| FY2017 | $2.2B | $4.0B |
| FY2016 | $1.8B | $850.0M |